Technology | May 13, 2015

Abbott, GE Healthcare Partner to Identify Source of Atrial Fibrillation

Integrated system brings together real-time patient data for assisting in faster analysis of complex heart rhythm disorders

Abbott, GE, CardioLab, RhythmView, atrial fibrillation, source

GE's CardioLab is one half of the integrated system with Abbott that will provide patient-specific data on the heart's electrical activity in real time.

May 13, 2015 — Abbott and GE Healthcare announced an agreement that will bring real-time, patient-specific data about the heart's electrical activity to cardiac electrophysiology labs. The goal of the collaboration is to speed up the diagnosis of the sources of atrial fibrillation and other heart rhythm disorders.

The integration of electrogram signal data from GE's CardioLab electrophysiology recording system into Abbott's RhythmView mapping software will allow doctors to use instantaneous electrical data of a person's heart to identify the sources of atrial fibrillation. By providing patient-specific diagnostics based on each person's unique physiology, this integrated system transforms current treatment approaches, which primarily rely on a one-size-fits-all anatomical approach.

Abbott's mapping software, or rotor identification system, helps physicians identify and target the specific areas of a person's heart that are perpetuating atrial fibrillation, the most common heart rhythm disorder. Abbott entered the catheter-based electrophysiology market last year through the acquisition of Topera Inc.

GE Healthcare’s CardioLab helps simplify the electrophysiology practice and streamline the workflow in diagnosis and treatment of complex cardiac cases.

For more information: www.abbott.com

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init